Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06690801 · ClinicalTrials.gov registry record

Dead Space and Inhaled Nitric Oxide in Pediatric Acute Respiratory Distress Syndrome

A clinical trial of Acute Respiratory Distress Syndrome, sponsored by Children's Hospital Los Angeles.

Recruiting
Registry status
1,260
Enrollment target
10
Study locations

NCT06690801: Recruiting study of Acute Respiratory Distress Syndrome, sponsored by Children's Hospital Los Angeles.

NCT06690801 is a study of Acute Respiratory Distress Syndrome that is actively recruiting participants, run by Children's Hospital Los Angeles. The registered enrollment target is 1,260 participants, above the 327-participant average among 31 other Acute Respiratory Distress Syndrome trials with a reported enrollment target (285% higher). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06690801, a study of Acute Respiratory Distress Syndrome, is actively recruiting participants, sponsored by Children's Hospital Los Angeles.

RECRUITING
Registry status
1,260 participants
Enrollment target
10
Study locations

Study Summary

The goal of this observational study is to determine whether a marker of dead space (the end-tidal to alveolar dead space fraction \[AVDSf\]) is more strongly associated with mortality risk than markers of oxygenation abnormality (oxygenation index) and to determine whether dead space (AVDSf) is an important marker of heterogeneity in the inhaled nitric oxide (iNO) treatment effect for children with acute respiratory distress syndrome (ARDS). The study aims are: 1. To validate AVDSf for risk stratification of mortality in pediatric ARDS 2. To determine if there is heterogeneity in treatment effect for iNO defined by AVDSf 3. To detect the association between AVDSf and microvascular dysfunction trajectory and whether iNO therapy modifies this association This is a prospective, multicenter observational study of 1260 mechanically ventilated children with moderate to severe ARDS. In a subgroup of 450 children with severe ARDS, longitudinal blood samples will be obtained to measure plasma protein markers.

Primary Outcome

28 day all-cause mortality

Study Locations (10)

Wisconsin

  • American Family Children's Hospital / University of Wisconsin-Madison - Madison
  • Children's Hospital of Wisconsin / Medical College of Wisconsin - Milwaukee

California

  • Children's Hospital Los Angeles - Los Angeles

Colorado

  • Children's Hospital Colorado - Denver

Massachusetts

  • Boston Children's Hospital - Boston

Michigan

  • University of Michigan / CS Mott Children's Hospital - Ann Arbor

Nebraska

  • University of Nebraska Medical Center / Children's Hospital and Medical Center - Omaha

Ohio

  • Cincinnati Children's Hospital Medical Center - Cincinnati

Pennsylvania

  • Children's Hospital of Philadelphia - Philadelphia

Trial Details

FieldValue
Enrollment Target 1,260 participants
Start Date 2024-10-03
Est. Completion 2029-02-01
Children's Hospital Los Angeles

119 total trials

What NCT06690801 shows while recruiting

NCT06690801 is an observational study that tracks outcomes without assigning an intervention. Its 1,260 participants enrollment target places it among the larger protocols in the corpus, above the 327-participant average among 31 other Acute Respiratory Distress Syndrome trials with a reported enrollment target (285% higher).

The record links to 1 condition, with Acute Respiratory Distress Syndrome appearing as the primary indexed condition, and to 0 interventions.

NCT06690801 lists 10 locations in 9 states (Wisconsin, California, Colorado).

Frequently Asked Questions

What is clinical trial NCT06690801 about?

NCT06690801 is a clinical study titled "Dead Space and Inhaled Nitric Oxide in Pediatric Acute Respiratory Distress Syndrome". The goal of this observational study is to determine whether a marker of dead space (the end-tidal to alveolar dead space fraction \[AVDSf\]) is more strongly associated with mortality risk than markers of oxygenation abnormality (oxygenation index) and to determine whether dead space (AVDSf) is an ...

What is the current status of trial NCT06690801?

This trial is currently recruiting. The enrollment target is 1,260 participants. The study started on 2024-10-03. Estimated completion is 2029-02-01.

What conditions does trial NCT06690801 study?

This clinical trial studies the following conditions: Acute Respiratory Distress Syndrome.

Who is sponsoring clinical trial NCT06690801?

This trial is sponsored by Children's Hospital Los Angeles, which has 119 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06690801 being conducted?

This trial has 10 study locations across California, Colorado, Massachusetts, Michigan, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Respiratory Distress Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06690801's enrollment target sits among peer trials

1,260 2nd of 31 the highest of 31 other Acute Respiratory Distress Syndrome trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Respiratory Distress Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06712316 · 1,260 participants · Phase 2

    Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

  • NCT06812273 · 1,260 participants · NA

    Mediators and Moderators of Auditory Training

  • NCT06931340 · 1,260 participants · Phase 3

    Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

  • NCT06119581 · 1,264 participants · Phase 3

    A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06690801, the US trial registry maintained by the National Library of Medicine. NCT06690801 (large enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.